scPharmaceuticals

Subcutaneous drug-device combination therapeutics (FUROSCIX) -- acquired by MannKind Corporation, Oct 2025

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
NKCC2Small molecule
Heart FailureChronic Kidney Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 July 2026ApprovalFurosemide (subcutaneous, scPharmaceuticals)FDA approves Furoscix ReadyFlow autoinjector for edema in HF and CKD
US, FDA · Source ↗

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$16M$4.1M$41M$18Mreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1$12M$4.6M$58M$20Mreport ↗
2024-Q3$10M$3.5M$91M$35Mreport ↗
2024-Q2$8.1M$2.7M$39M$17Mreport ↗
2024-Q1$6.1M$2.7M$58M$14Mreport ↗
2023-Q3$3.8M$3.4M$35M$16Mreport ↗
2023-Q2$1.6M$2.9M$71M$14Mreport ↗
2023-Q1$2.1M$2.1M$75M$11Mreport ↗
2022-Q3—$3.7M$41M$10Mreport ↗
2022-Q2—$5.1M$41M$9.7Mreport ↗
2022-Q1—$4.3M$52M$7.7Mreport ↗
2021-Q3—$3.7M$80M$6.5Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$36M$12M$76M$85Mreport ↗

scPharmaceuticals reported revenue of $36.33M, up 167.3% YoY, R&D spend of $12.1M, up 2.5% YoY, cash and equivalents of $75.66M, and a quarterly net burn of $85.15M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$14M$12M$47M$55Mreport ↗
2022-FY—$16M$71M$37Mreport ↗
2021-FY—$16M$74M$28Mreport ↗